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ABSTRACT 
The B cell survival factors APRIL and BLyS are important for B cell maturation and activation 
and contribute to human autoimmune diseases. Interference with B cell function by targeting 
these molecules is currently being investigated in large clinical trials for systemic lupus 
erythematosus. The local expression patterns of APRIL and BLyS have not been 
investigated in detail in kidneys with lupus nephritis. We studied the mRNA expression of 
APRIL, BLyS, and the corresponding receptors BCMA, TACI, and BAFF-R in microdissected 
human biopsies with proliferative lupus nephritis (n=25) and compared it with pretransplant 
biopsies of living donors (n=9). APRIL and BLyS mRNA levels were significantly higher in 
glomeruli of patients with proliferative lupus nephritis (12- and 30-fold, respectively). 
Tubulointerstitial expression of APRIL, BLyS, BCMA, and TACI was also significantly 
elevated. To localise the respective proteins in the kidney, APRIL, BLyS and BAFF-R were 
studied by immunohistochemistry in renal biopsies with proliferative (n=21) or membranous 
(n=8) lupus nephritis. APRIL was prominently expressed in glomeruli with proliferative, but 
not membranous lupus nephritis. The staining pattern was consistent with mesangial cells. A 
prominent accumulation of CD68 positive cells was present in glomeruli in association with 
APRIL expression. APRIL, BLyS and BAFF-R were also expressed in interstitial 
inflammatory cell accumulation. This is the first study, which details local expression of 
APRIL and BLyS in glomeruli and tubulointerstitium of human proliferative lupus nephritis. 
This information might help define intrarenal effects of APRIL and BLyS inhibition in human 
lupus nephritis. 
Keywords: APRIL, BLyS, BAFF-R, gene expression, lupus nephritis 
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INTRODUCTION 
Renal involvement in systemic lupus erythematosus is a severe complication with major 
impact on morbidity and mortality.1 Immunosuppressive therapy with cyclophosphamide or 
mycophenolate mofetil has been shown to improve the renal outcome of lupus nephritis 
considerably.1-2 Although a mainstay of therapy, these treatments are associated with serious 
side effects.1-2 Therefore, more specific therapeutic approaches to this systemic disease are 
being intensively evaluated.  
B cells are considered to be involved in lupus nephritis particularly as a source for 
nephritogenic auto-antibodies.3 The B cell survival factors belonging to the tumor necrosis 
factor superfamily, i.e. TNFSF13/APRIL (member 13/ a proliferation inducing ligand) and 
TNFSF13B/BLyS (member 13B/ B lymphocyte stimulator, or BAFF for B cell activating 
factor), play a pivotal role in B cell biology. APRIL and BLyS are expressed by monocytes, 
macrophages, dendritic cells, T cells, B cells, but also non-hematopoietic cells, e.g. cancer 
cells.4-5 The three known receptors of the mentioned ligands are TNFRSF13C/BAFF-R 
(tumor necrosis factor receptor superfamily, member 13C/ B cell activating factor receptor), 
TNFRSF17/BCMA (member 17/ B cell maturation antigen), and TNFRSF13B/TACI (member 
13B/ transmembrane activator and CAML-interactor). BAFF-R has a strong selectivity for 
BLyS, whereas BCMA has a higher affinity for APRIL, and TACI binds both ligands equally.4 
APRIL may also bind to heparan sulphate proteoglycans.6-7 The receptors for BAFF and 
APRIL are mainly expressed on B cells.4 In addition to the well established role in B cell 
survival, these factors exert functions on different subsets of cells, e.g. T cells4-5 and 
monocytes.8-9  
In systemic lupus erythematosus, APRIL and BLyS have been shown to be involved in the B 
cell mediated pathology.10 Transgenic mice with constitutive overexpression of BLyS show 
lupus-like features.11-12 In contrast, APRIL-transgenic mice manifest only subtle 
abnormalities.13 In lupus mouse models, circulating BLyS levels were found to be elevated12 
and interventions into the APRIL/BLyS system ameliorated proteinuria and renal 
inflammation.12, 14-15 Consistently in human systemic lupus erythematosus, serum as well as 
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blood mRNA levels of APRIL and BLyS were found to be elevated.16-18 While depleting B 
cells by an anti-CD20 antibody, e.g. by rituximab, surprisingly failed to show significant 
benefit for patients with renal and non-renal systemic lupus erythematosus19, phase II/III 
clinical trials investigating the blockade of the APRIL/BLyS system in systemic lupus 
erythematosus have been initiated (LBSLO2/99 NCT00071487 and NCT 00583362; BLISS-
76/NCT00410384 and BLISS-52/NCT00424476; NCT00624338) and promising results have 
been reported.20-21 
Although systemic therapies targeting APRIL and BLyS have reached the stage of clinical 
trials, no detailed data on local renal expression of this system in human proliferative lupus 
nephritis are currently available. We hypothesised that a complex expression of players in 
this local APRIL/BLyS system might be involved in renal tissue injury and might even be a 
future therapeutic target. Therefore, to better understand the tissue specific responses in 
interventional trials in systemic lupus erythematosus, we localised and quantified members of 
this system in human biopsies with proliferative lupus nephritis. 
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MATERIALS AND METHODS  
Renal Biopsies and mRNA analysis 
Human renal biopsy specimens were procured in an international multicenter study, the 
European Renal cDNA Bank ─ Kröner-Fresenius biopsy bank (see Acknowledgments). All 
biopsy cores were obtained for routine diagnostic purposes (i. e. light microscopy, 
immunofluorescence, and electron microscopy) and reviewed by experienced renal 
pathologists. The characteristics of all patients are shown in Table 1. We used the ISN/RPS22 
classification, which divides proliferative glomerular lesions into class III (focal disease, i.e. 
less than 50 percent of glomeruli affected) and IV (diffuse disease, i.e. more than 50 percent 
of glomeruli affected); membranous lupus nephritis is categorized as class V. Real-time 
reverse transcriptase–PCR (real-time RT-PCR) was performed on biopsy specimen from 
patients with systemic lupus erythematosus and lupus nephritis ISN/RPS22 III or IV with 
active lesions (n=24 for APRIL and BLyS in glomeruli, n=21 for APRIL, BLyS and their 
receptors in the tubulointerstitium) and control subjects (living donors, n=6 for glomerular and 
n=5 for tubular analyses).  
After informed consent and with approval of the local ethics committees a cortical tissue 
specimen was separated from one of the newly obtained, unfixed biopsy cores. This sample 
was transferred to RNase inhibitor and microdissected into glomerular and tubular specimen. 
RNA isolation and real-time RT-PCR was performed as previously reported.23 Pre-developed 
TaqMan reagents were used for human TNFSF13, TNFSF13B, TNFRSF13B, TNFRSF13C, 
TNFRSF17 and the reference genes 18S rRNA and GAPDH (Applied Biosystems, 
Darmstadt, Germany). The expression of candidate genes was normalised to both reference 
genes giving similar results. All fold-changes shown are normalised to GAPDH. The mRNA 
expression was analysed by standard curve quantification. 
Renal Biopsies and Immunohistochemistry 
Immunohistochemistry was performed on biopsies not used for the mRNA analyses. 
Included were biopsies from patients with proliferative (type IV, n=21) or membranous (type 
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V, n=8) lupus nephritis. Immunohistochemistry was performed as previously described.24-25 In 
brief, dewaxed and rehydrated renal biopsy sections were incubated in 3% hydrogen 
peroxide to block endogenous peroxidases. The Avidin/Biotin blocking Kit (Vector, 
Burlingame, CA) was used to block endogenous biotin. An autoclave oven was used for heat 
based antigen retrieval in Antigen retrieval solution (Vector). Incubation with the primary 
antibodies was performed for 1 hour in 10% non-fat dry milk. Incubation with biotinylated 
secondary antibodies (Vector) for 30 minutes was followed by the ABC reagent (Vector). 
3’3’Diaminobenzidine (DAB, Sigma, Taufkirchen, Germany) with metal enhancement served 
as detection system. As primary antibodies we used: polyclonal serum against APRIL (US 
Biological, Swampscott, MA26), monoclonal BLyS antibody (Alexis Biochemicals, Lausen, 
Switzerland27-28), and monoclonal BAFF-R antibody (Clone 11C1, Alexis Biochemicals27).The 
monoclonal mouse anti-CD68 antibody (Clone PG-M1, DAKO Germany, Hamburg) has 
previously been used extensively in formalin fixed, paraffin embedded renal biopsies.29 
Negative controls were performed on sections of allograft nephrectomies and human tonsils 
with a non-immune rabbit serum.  
Cell culture 
Human mesangial cells30 were cultured as previously reported. Except for controls they were 
stimulated with the indicated reagents and concentrations (n=3 or n=4 wells for each 
condition): universal type 1 interferon IFN alpha (1000 U/ml; PBL InterferonSource, NJ, 
USA), recombinant human interferon IFN beta (1000 U/ml; R&D Systems, Abingdon, UK), 
recombinant human interferon IFN gamma (1000 U/ml; R&D Systems, Abingdon, UK), 
recombinant human interleukin IL 2 (5ng/ml; R&D Systems, Abingdon, UK) and recombinant 
human tumor necrosis factor TNF alpha (25ng/ml; R&D Systems, Abingdon, UK). Also, a 
combination of the three interferons as well as a combination of IFN gamma and TNF alpha 
in the above concentrations was used. Cells were harvested at 12 and 24 hours. Total 
cellular RNA was extracted using the Qiagen RNeasy kit (Qiagen, Hombrechtikon, 
Switzerland). The mRNA expression was analysed by real-time RT-PCR. 
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Statistics 
Experimental data are given as mean and standard deviation (mean ± standard deviation). 
Statistical analysis was performed using Kruskal-Wallis-Test, Mann-Whitney-U-Test, and 
Pearson’s correlation test (SPSS 17.0). P-values less than 0.05 were considered to indicate 
statistically significant differences. 
 
RESULTS 
Glomerular and tubulointerstitial APRIL and BLyS mRNA levels are increased in 
proliferative lupus nephritis 
Real-time RT-PCR was performed to quantify the mRNA expression of APRIL, BLyS, BAFF-
R, BCMA, and TACI in microdissected human renal biopsies. The clinical and morphological 
data of the patients included in the study are summarised in Table 1. APRIL and BLyS 
mRNA expression was significantly higher in microdissected glomeruli from patients with 
proliferative lupus nephritis as compared to controls (fold-induction of APRIL: 11.6 ± 22.4, p< 
0.05 and BLyS: 29.8 ± 47.1, p< 0.01, Figure 1A and B). In the tubulointerstitial 
compartment, an induction of APRIL and BLyS mRNAs was also found in lupus nephritis 
compared to controls (fold-induction of APRIL: 12.6 ± 25.3, p< 0.01 and BLyS: 57.7 ± 93.9 p< 
0.01, Figure 1C and D). Subgroup analysis revealed that the above results were also true if 
ISN/RPS III and IV classes were studied separately (data not shown). Real-time RT-PCR for 
the receptors, BAFF-R, BCMA, and TACI, revealed glomerular mRNA expression, which was 
too low to be quantified. In the tubulointerstitium, mRNA levels for TACI and BCMA were 
significantly higher in lupus nephritis compared to controls (fold-induction 109.0 ± 305.4, p< 
0.05, 135.8 ± 332.1, p<0.01 respectively, Figure 1E and F). BAFF-R mRNA showed very 
low expression levels in lupus nephritis and controls and no significant induction (not 
illustrated). Again subgroup analysis revealed that the above results were found in both 
ISN/RPS III and IV lupus nephritis (data not shown).  
Neusser et al.: Intrarenal APRIL and BLyS 
9 
 
Glomerular expression of APRIL mRNA correlated positively with glomerular expression of 
BLyS mRNA (r= 0.93, p<0.01). It also showed positive correlation with tubulointerstitial 
expression of APRIL (r= 0.86, p<0.01), BLyS (r= 0.93, p<0.01), BCMA (r= 0.94, p <0.0.1) and 
TACI mRNA (r= 0.92, p < 0.01). Glomerular expression of BLyS mRNA also correlated with 
tubulointerstitial expression of APRIL (r= 0.97, p<0.01), BLyS (r= 0.96, p<0.01), BCMA (r= 
0.89, p <0.01) and TACI mRNA (r= 0.82, p < 0.01). No significant correlation was found 
between APRIL or BLyS mRNAs with serum creatinine, proteinuria, or ISN/RPS stage in 
either glomeruli or tubulointerstitium, respectively. 
 
Glomerular expression of APRIL protein in proliferative, but not in membranous lupus 
nephritis 
To further describe the morphological distribution of APRIL, we used immunohistochemistry 
on formalin-fixed, paraffin embedded renal biopsies. Allograft nephrectomies and human 
tonsils were used to establish the immunohistochemical application of a commercial antibody 
(Figure 2). A very reliable staining pattern was established with a heat based antigen 
retrieval (Figure 2 A, C). Controls using an isotype matched immunoglobulin were negative 
(Figure 2 B, D). Immunohistochemisty was then performed on a total of 29 renal biopsies 
from patients with either proliferative (ISN/RPS IV, n=21) or membranous (ISN/RPS V, n=8) 
lupus nephritis. 
The biopsies from patients with proliferative lupus nephritis demonstrated a prominent 
mesangial expression of APRIL (Figure 3 A, B, E). The APRIL staining was particularly 
prominent at the vascular pole (Figure 3 C, E). Eleven of the 21 biopsies also demonstrated 
a mesangial APRIL expression. Only one biopsy was completely negative in glomeruli. 
Furthermore, APRIL was found to be present in parietal epithelial cells in 14 of 21 biopsies. 
As expected APRIL was also positive in inflammatory cells of glomeruli and the 
tubulointerstitium in lupus nephritis (Figure 3 D).5 An accumulation of CD68 positive 
monocytes/macrophages was present in glomeruli with prominent expression of APRIL 
(Figure 3 E, F). 
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In the renal biopsies from patients with membranous lupus nephritis, the glomeruli were most 
commonly negative for APRIL (Figure 2 E, F). Five of the eight biopsies demonstrated 
APRIL positive cells at the vascular pole. Within the glomerular tuft, 6 biopsies were negative 
or demonstrated faint staining. Only two biopsies demonstrated a mesangial pattern. APRIL 
positive parietal epithelial cells were only present in one out of eight biopsies with 
membranous lupus nephritis. In contrast, BLyS protein was only detected in inflammatory 
infiltrates in the tubulointerstitium in selected cases (not illustrated). 
Expression of BAFF-R was restricted to a small population of infiltrating cells. These cells 
were particularly seen in nodular inflammatory cell accumulation consistent with B cells, 
(Figure 3 H, compared with the consecutive expression of APRIL in G). Expression by 
intrinsic renal cells was not detected.  
 
Cell culture 
To further examine the mesangial expression of APRIL seen by immunohistochemistry we 
studied APRIL expression in vitro. In cultured mesangial cells, very low basal mRNA 
expression for APRIL was found (mean Ct value: 36 ± 1; n=3)).30 No rise in APRIL mRNA 
was seen under proinflammatory stimulation with interferon alpha, -beta, -gamma, interleukin 
2 and human tumor necrosis factor alpha (data not shown). 
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DISCUSSION 
In this study we provide the first detailed data on intrarenal expression of APRIL, BLyS and 
their receptors in human lupus nephritis. These data are particularly important as 
interventions into the APRIL/BLyS system are currently evaluated in several multicenter 
studies aimed primarily at systemic effects of B cell interference in systemic lupus 
erythematosus.20-21 
Data on intrarenal expression patterns of the B cell survival factors are scarce. A local 
infiltration of the kidneys by APRIL and BLyS positive B cells was recently described.31 This 
study lacked detailed description of the biopsy material used. Therefore, in the present study, 
we used a number of biopsies with well described morphological groups of lupus nephritis. In 
our study, we demonstrate a strong increase of APRIL mRNA by real-time RT-PCR in 
microdissected glomeruli from patients with proliferative lupus nephritis. The corresponding 
receptors in this renal compartment remain to be elucidated. Due to the low level of mRNA 
expression we were not able to clarify by real-time RT-PCR which receptor might be targeted 
in the glomerular injury process. In the tubulointerstitium, we found mRNA for both ligands as 
well as the receptors TACI and BCMA induced. Additionally, we found very low expression of 
BAFF-R mRNA, which is in line with the localisation to a minor population of BAFF-R positive 
cells infiltrating the interstitium described below.  
For immunohistological confirmation studies, we paid special attention to glomeruli as lupus 
nephritis presents initially as a glomerular disease and the ISN/RPS classification is based 
on glomerular rather than tubulointerstitial pathology.22 Surprisingly, besides the expected 
expression of APRIL in inflammatory cells, the morphological pattern of distribution was 
consistent with autochthonous mesangial cells. This is in contrast to Chu et al.31, who 
described renal APRIL expression solely in infiltrating B lymphocytes. As it is unclear, which 
classes of lupus nephritis were included in Chu’s study, and as we could not consistently 
detect APRIL in mesangial cells of membranous lupus nephritis, our finding of APRIL in 
mesangial cells may indeed indicate a rather specific finding in proliferative lupus nephritis. 
However, our results of mesangial cells expressing APRIL are in line with the well 
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documented expression of APRIL by cells other than those of the hematopoietic lineage, e.g. 
non-hematopoietic, non-immune cells in solid tumors32-33 and in other cells like osteoclasts.5 
In the tubulointerstitium, APRIL could be localised to infiltrating inflammatory cells, in line with 
the report by Chu et al.. Also, BLyS could be localised by us to inflammatory infiltrates in the 
tubulointerstitium in selected cases. While we detected by immunohistochemistry a more 
pronounced signal for APRIL than BLyS, we found strong positive correlations between 
mRNA levels of APRIL and BLyS. The corresponding BAFF-R was tracked by us to a small 
population of interstitial infiltrating cells. In sum, the B cell survival factors are involved locally 
in glomeruli and tubulointerstitium of lupus nephritis and, surprisingly, intrinsic renal cells 
rather than merely immigrating inflammatory cells expressed APRIL in the glomerulus. 
In agreement with our data on a local role for APRIL and BLyS in lupus nephritis, 
components of this system have been described locally in target organs in various other 
autoimmune diseases: In human multiple sclerosis, APRIL protein was found in the 
cerebrospinal fluid34, BLyS mRNA was detected in cerebral lesions, and BLyS protein is 
expressed by astrocytes in multiple sclerosis lesions.35 As BAFF-R positive inflammatory 
cells are seen near BLyS positive astrocytes, BLyS has been speculated to support plasma 
cell mediated inflammation.35 This local expression of BLyS and BAFF-R in multiple sclerosis 
is somewhat reminiscent of that described by us in lupus nephritis for APRIL in mesangial 
cells and inflammatory cells in their vicinity. In human Sjögren’s syndrome, 
immunohistochemical evidence for BLyS production in epithelial cells of salivary glands 
exists.28,36 BLyS-positive monocytes37, B-38 and T-37 lymphocytes as well as BAFF-R-positive 
B lymphocytes38 infiltrating salivary glands in Sjögren’s syndrome have been demonstrated, 
similar to the BLyS-/BAFF-R-positive interstitial cell infiltrate seen in lupus nephritis. In 
human rheumatoid arthritis, different cells seem to express the B cell survival factors: one 
immunohistochemical study found APRIL in germinal center positive synovitis in CD83 
positive dendritic cells whereas BLyS was derived from CD68 positive 
monocytes/macrophages.39 Other studies on human rheumatoid arthritis described APRIL in 
mononuclear cells and lymphocytes infiltrating the synovial area.40 BLyS and BAFF-R protein 
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were also described to be expressed by synovial monocytes as well as T and B 
lymphocytes.27 Consistently, in lupus nephritis we found BLyS and BAFF-R in a small 
population of inflammatory cells in the interstitium. In human rheumatoid arthritis, APRIL and 
BLyS are locally expressed by intrinsic fibroblast-like synoviocytes.27, 40-41 The expression of 
APRIL by local fibroblast-like synoviocytes in rheumatoid arthritis is somewhat similar to the 
APRIL expression by mesangial cells in lupus nephritis. Interestingly, we could show low 
basal expression levels of APRIL mRNA in cultured mesangial cells.30 However, we could not 
demonstrate increased APRIL mRNA expression by this cell line under proinflammatory 
stimulation. As the glomerular APRIL expression is only found in ISN/RPS III and IV lupus 
nephritis but not in ISN/RPS V, we may have failed to sufficiently mimic the specific 
glomerular milieu of proinflammatory mediators or stimulation by immune complexes 
Based on the above descriptive data on local expression of APRIL and BLyS and the data 
mentioned in other autoimmunopathies several hypotheses can be formulated. APRIL has 
been shown to downregulate apoptosis, e.g. in lymphoma B cells.42-43 Mesangial cell derived 
APRIL may promote survival and proliferation in an autocrine or paracrine, e.g. proteoglycan-
receptor-mediated, fashion leading to increased glomerular cellularity.6,44-45 On the other 
hand, the expression of BLyS and BAFF-R in inflammatory cells of the interstitium in lupus 
nephritis, as described by us, may help sustain autocrine B31 and T lymphocyte mediated 
inflammation in the tubulointerstitial compartment of kidneys with lupus nephritis. In the 
glomerular compartment, few T cells, even fewer B cells and no dendritic cells are typically 
present.29,46-47 Thus, macrophages, which we and others48 could identify in glomeruli with 
lupus nephritis, may play a prominent role. Chang et al. show in vitro that BLyS stimulation of 
TACI expressing monocytes led to enhancement of their survival and their activation.9 Willen 
et al. 8 show in in vitro experiments that APRIL binds to monocytes via proteoglycans and 
TACI, mediating different effects such as monocyte adhesion. APRIL and BLyS may thus be 
potential ligands of monocytes infiltrating lupus nephritis glomeruli. In support of this 
hypothesis, we found monocytic infiltrates in close proximity to APRIL expressing mesangial 
cells. 
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In summary, our detailed analyses of the intrarenal expression of APRIL, BLyS and their 
receptors add the glomerular mesangium to the list of cellular compartments capable of local 
ligand expression. As in arthritis the role of this local production in the course of disease has 
still to be elucidated. However, our data might help interpret the up-coming results of 
APRIL/BLyS interference in autoimmunopathies with renal manifestations such as lupus 
nephritis. 
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Tables and Table legends: 
Table 1: Clinical and histological characteristics of the samples used for real-time RT-
PCR 
If not specifically indicated, the samples were used for both glomerular (GA) and 
tubulointerstitial (TA) analyses. Histology is given according to the ISN/RPS classification.22 
Patients’ age is given in years, serum creatinine in µmol/L (mg/dl), proteinuria in g/day. “n.a.”, 
“not available”; SLE, systemic lupus erythematosus; LD, living donor. 
sample histology age sex creatinine proteinuria 
SLE 1 GA III 37 f 79 (0.9) 2.40 
SLE 2 III 22 f 70 (0.8) 3.20 
SLE 3 III 50 f 106 (1.2) 0.80 
SLE 4 III n.a. n.a. 106 (1.2) 2.10 
SLE 5 III 37 n.a. 106 (1.2) 1.78 
SLE 6 III 29 f 65 (0.7) n.a. 
SLE 7 III 28 f 90 (1.0) 1.00 
SLE 8 III 19 f 73 (0.8) 13.00 
SLE 9 IV 35 f 62 (0.7) 2.00 
SLE 10 IV 29 f 97 (1.1) 1.00 
SLE 11 IV 46 f 282 (3.2) 10.60 
SLE 12 IV 45 f 141 (1.6) 4.20 
SLE 13 IV 72 m 114 (1.3) 1.75 
SLE 14 IV 42 f 141 (1.6) 0.71 
SLE 15 IV 46 m 97 (1.1) 2.10 
SLE 16 IV 51 f 69 (0.8) 5.00 
SLE 17 GA IV 43 f 86 (1.0) 4.00 
SLE 18 IV 28 f 264 (3.0) 4.00 
SLE 19 IV 17 f 194 (2.2) 8.80 
SLE 20 IV 26 f 158 (1.8) 1.70 
SLE 21 IV 42 f 79 (0.9) 2.90 
SLE 22 IV 19 f 158 (1.8) 3.30 
SLE 23TA IV 31 m 125 (1.4) 8.00 
SLE 24 GA IV 18 f 141 (1.6) 3.50 
SLE 25 GA IV 51 f 79 (0.9) 0.50 
LD 1 GA normal 35 f < 88 (1.0) < 0.2 
 LD 2 GA normal 56 f < 88 (1.0) < 0.2 
LD 3 GA normal 41 m < 88 (1.0) < 0.2 
LD 4 GA normal 62 m < 88 (1.0) < 0.2 
LD 5 normal 27 m < 88 (1.0) < 0.2 
LD 6 normal n.a. n.a. < 88 (1.0) < 0.2 
LD 7 TA normal 58 f < 88 (1.0) < 0.2 
LD 8 TA normal 56 f < 88 (1.0) < 0.2 
LD 9 TA normal 70 f < 88 (1.0) < 0.2 
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Figure legends: 
 
Figure 1: Expression of mRNA for APRIL and BLyS and their receptors in human 
proliferative lupus nephritis and control tissue 
APRIL and BLyS mRNA are increased in glomeruli (A,B) as well as the tubulointerstitial 
compartment (C,D) in human proliferative lupus nephritis (LN) compared to living donors 
(LD). The mRNA levels for the receptors TACI and BCMA are increased in the 
tubulointerstitial compartment of kidneys with lupus nephritis (E, F). BAFF-R mRNA showed 
very low constitutive expression with no clear induction in disease (not shown). * and ** 
indicate p< 0.05 and p< 0.01, respectively.  
 
Figure 2: Establishment of the anti-APRIL antibody for immunohistochemistry and 
expression in membranous lupus nephritis 
Immunohistochmistry was performed with a polyclonal antibody against human APRIL (A, C, 
E), an isotype control immunoglobulin (B, D), or CD68 (F) on human tonsil (A, B), an allograft 
nephrectomy (C, D) and a biopsy with membranous lupus nephritis (E, F). In the allograft 
nephrectomy, prominent expression was found in parietal epithelial cells (arrow) in some 
glomeruli, but no significant expression within the glomerular tuft. B, D: Note the absence of 
positive color product in the controls. E, F: In this biopsy with membranous lupus nephritis, 
APRIL staining within the glomerular tuft was absent. The arrow in E highlights an APRIL 
positive cell within the tubulointerstitium. Scattered CD68 positive monocytes/macrophages 
were present within glomerular capillaries (arrowhead in F). 
 
Figure 3: Localisation of APRIL in proliferative lupus nephritis  
Immunohistochemistry was performed with a polyclonal antibody against human APRIL (A-E, 
G), a monoclonal antibody against CD68 (F) and a monoclonal antibody against BAFF-R (H) 
on renal biopsies with proliferative lupus nephritis. Prominent expression of APRIL in a 
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mesangial pattern is illustrated in A (arrow), with some positivity along peripheral capillary 
walls. Positive staining at the vascular pole was also commonly detectable (arrow in B, also 
C, E). Positivity of interstitial infiltrating cells is shown in D (arrow). E, F: Consecutive staining 
for CD68 shows prominent accumulation of macrophages in the glomerular tuft (some 
illustrated by arrows in F). G, H: Consecutive sections stained for APRIL and BAFF-R are 
illustrated. Some interstitial infiltrating cells are positive for APRIL (arrow in G). Only a small 
population of interstitial infiltrating cells, consistent with B cells, demonstrated expression of 
BAFF-R (H). 
A B
C D
E F
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